Skip to main content
| News

New at Switzerland Innovation Park Basel Area: Coretag

09.01.2020

Coretag, a new dynamic biotech company, launches a radioligand platform technology for a range of therapeutic and diagnostic purposes. A radioligand is a radioactive biochemical that is used for diagnostic and therapeutic procedures or for studying the body’s receptor systems. Injected into the relevant tissue or administered into the bloodstream, the radioligand binds to its receptor on tumor cells surfaces. Coretag is determined to rapidly improve care with this platform technology.

Coretag: Elmer Monster, Ermond van Beek, Markwin Maring and Jan van Bodegom (from left to right), img: Roderik van Nispen

Coretag aims to launch an application named NC-Scan for use in patients in 2021. Based on selectively binding to necrotic cells, the NC-Scan will be the world’s first clinical application to determine chemotherapy efficacy within the first week of therapy. Clinical trials with patients with specific solid tumors will start early 2020 at world-renowned leading cancer institutes in Europe and the USA.

This application is a basis for the development of therapeutic agents. Two radioligands therapeutics are in the pipeline, both for the treatment of solid tumor cancer-types. Based on brachy-therapy and hyperthermia, they will have major impact as adjuvant to many existing forms of cancer therapies that are not 100% effective yet.

Coretag’s executive team, originally from the Netherlands, sets its base at the Switzerland Innovations Park Basel Area. They work focused on developing their business. “We are very happy with this location. The atmosphere is dynamic and based on progress. That is how we stand. Great to be here”, says CFO Elmer Monster.

Links

Coretag
Coretag on LinkedIn

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
1 2 3 59

Do you have a question? We'd like to hear from you.